

Tab 107

## **Throckmorton, Douglas C**

---

**From:** Temple, Robert  
**Sent:** Monday, October 07, 2002 6:16 PM  
**To:** Prettyman, Buddy; Temple, Robert  
**Cc:** Orloff, David G; Throckmorton, Douglas C; Temple, Robert  
**Subject:** RE:

Buddy, by this E-mail I am asking David Orloff to look at the suggestions and make some of his own. Doug, the reason you're on this is that the Boozer study had at least some increase in BP over its course; also the pharmacology of ephedrine could be an issue.

-----Original Message-----

**From:** Prettyman, Buddy  
**Sent:** Monday, October 07, 2002 3:30 PM  
**To:** Temple, Robert  
**Subject:**  
**Importance:** High

Dr. Temple,

The Department is going to push hard for the "raw data" from the Boozer-Daly study. According to the lawyers, we are not going to get it without our commitment to including some non-FDA experts in the review. Here is some names that I got from Dr. Paul Coates at NIH. Could you have someone check to see if CDER has some SGE's on the books that could be used for this purpose also (I would expect someone in Cardiology, Obesity, Pharmacology of stimulants, Epidemiology). We need names by this Friday. Thanks.

Charles (Buddy) Prettyman  
Senior Policy Advisor to the Center Director  
Center for Food Safety and Applied Nutrition  
5100 Paint Branch Parkway, Rm. 4B-071  
(301) 436-1596 - direct  
(301) 436-2240 - Assistant (Roblyn Gest)  
(301) 436-2668 - fax

Suggested Reviewers